Discover and read the best of Twitter Threads about #IDJClub
Most recents (4)
🤔 📖 📱
Is Twitter The New ID Textbook?
Bugs, Drugs, and Social Media – Twitter as a Tool for Advancing the Field of Infectious Diseases
My #ECCMID2022 slides as a 🧵 1/n
Is Twitter The New ID Textbook?
Bugs, Drugs, and Social Media – Twitter as a Tool for Advancing the Field of Infectious Diseases
My #ECCMID2022 slides as a 🧵 1/n
Many ingredients in the kitchen of social media can be combined to create different products which supports advancing ID through SM.
Each activity can support one or multiple domains of 🧠 Blooms Taxonomy.
Get creative with your recipes to create new fun stuff! 2/n
Each activity can support one or multiple domains of 🧠 Blooms Taxonomy.
Get creative with your recipes to create new fun stuff! 2/n
One of the best accounts out there on SM @DGlaucomflecken - huge reach in short period, recent ASP skit in vertical video, very entertaining & original, uses several SM platforms.
REMEMBERING domain: ⚠️ beware inappropriate meropenem prescribing.
3/n
REMEMBERING domain: ⚠️ beware inappropriate meropenem prescribing.
3/n
#Remdesivir new trial just published
Here are the clinical implications:
Canadian trial (CATCO) in hospitalized patients with #COVID19 bit.ly/33uktIf
Compared to ACTT-1 trial bit.ly/3msi1In in patients on supplemental O2 as recommended by guidelines
🧵1/
Here are the clinical implications:
Canadian trial (CATCO) in hospitalized patients with #COVID19 bit.ly/33uktIf
Compared to ACTT-1 trial bit.ly/3msi1In in patients on supplemental O2 as recommended by guidelines
🧵1/
Both CATCO and ACTT-1 trials showed
-No liver or renal toxicity with remdesivir, and
-No safety differences between remdesivir and controls in over 2300 patients
Thus, both trials show that remdesivir is safe, prevents intubation, and reduces mortality
3/
-No liver or renal toxicity with remdesivir, and
-No safety differences between remdesivir and controls in over 2300 patients
Thus, both trials show that remdesivir is safe, prevents intubation, and reduces mortality
3/
Confused about remdesivir in light of the Solidarity trial?
Some experts say the data prove no general mortality benefit. Others say the study was flawed.
Fortunately there have been thoughtful analyses on Twitter from smart & respected ID experts which I’ve threaded together👇
Some experts say the data prove no general mortality benefit. Others say the study was flawed.
Fortunately there have been thoughtful analyses on Twitter from smart & respected ID experts which I’ve threaded together👇
Firstly, how did we get here? A review of the timeline of remdesivir studies and their findings by @zchagla
Thoughtful analysis in the conflicting data from Dr Paul Sax, one of the most respected ID minds around
1/ A #MedTweetorial on #HowIReadThisPaper for #DISCOVERYtrial - dex edition on @medrxivpreprint. We’ll be exploring the pre-print, supplement, and trial document. Would love for feedback, thoughts, & comments!
Currently, what is your opinion on using dexamethasone?
Currently, what is your opinion on using dexamethasone?
2/ Trial info:
▶️RCT, open-label, adaptive
▶️6,425 pts enrolled
▶️Dex 6mg daily for 10d (PO or IV) v usual care (1:2 ratio, respectively)
▶️176 🏥in UK
▶️Prim Outcome: OS
🔑Intention-to-treat
🔑Pre-specified stats plan
🔑Not randomized by O2 status
▶️RCT, open-label, adaptive
▶️6,425 pts enrolled
▶️Dex 6mg daily for 10d (PO or IV) v usual care (1:2 ratio, respectively)
▶️176 🏥in UK
▶️Prim Outcome: OS
🔑Intention-to-treat
🔑Pre-specified stats plan
🔑Not randomized by O2 status
3/ Results - Table 1
✅Well-balanced between dex & usual care
▶️Younger, less-comorbid cohort on vent
▶️Days of illness ⬆️w/ ⬆️O2
Imbalances in O2/vent cohort raises ❓s
1️⃣How to account for O2 & vent?
2️⃣Can we adjust & trust result?
✅Well-balanced between dex & usual care
▶️Younger, less-comorbid cohort on vent
▶️Days of illness ⬆️w/ ⬆️O2
Imbalances in O2/vent cohort raises ❓s
1️⃣How to account for O2 & vent?
2️⃣Can we adjust & trust result?
